Autoimmune encephalitis caused by antibodies to membrane and synaptic antigens
Abstract
In the past decade great advances were made in the field of autoimmune encephalitis. Several new antibodies targeting membrane and synaptic antigens were discovered. Tis discovery helped to elucidate the mechanism of many potentially lethal but treatment-responsive forms of acute encephalitis. In this review we present the field of autoimmune encephalitis caused by antibodies to membrane and synaptic antigens. We also present the clinical picture associated with specific antibody
Downloads
References
Jmor F, Emsley HCA, Fischer M, Solomon T, Lewthwaite P. Te incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virology Journal. 2008;5(1):134.
Schubert RD, Wilson MR. A tale of two approaches. Current opinion in neurology. 2015;28(3):283–7.
Bale JF. Virus and Immune-Mediated Encephalitides: Epidemiology, Diagnosis, Treatment, and Prevention. Pediatric Neurology. 2015;53(1):3–12.
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. Te Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses Tat of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project. Clinical Infectious Diseases. 2012;54(7):899–904.
Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77:179–189.
Ances BM, Vitaliani R, Taylor RA. Treatment-responsive limbic encephalitis identifed by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764–1777.
Dalmau J, Tüzün E, Wu H. Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis Associated with Ovarian Teratoma. Ann Neurol. 2007;61:25–36.
Lancaster E. Paraneoplastic Disorders. CONTINUUM: Lifelong Learning in Neurology. 2015;21:452–75.
Waters PJ, Irani SR. Neurexin-3α. Neurology. 2016;86(24):2222–3.
Vollmer TL, McCarthy M. Autoimmune encephalitis. Neurology. 2016;86(18):1655–6.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology. 2013;12(2):157–65.
Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome: Table 1. Neurology–Neuroimmunology Neuroinflammation. 2015;2(4):e130.
Darnell RB, Posner JB. Paraneoplastic Syndromes Involving the Nervous System. N Engl J Med. 2003;349:1543–1554.
Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis: Five new things. Neurology: Clinical Practice. 2012;2(3):215–23.
Rubio-Agusti I, Salavert M, Bataller L. Limbic Encephalitis and Related Cortical Syndromes. Current Treatment Options in Neurology. 2012;15(2):169–84.
Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Annals of the New York Academy of Sciences. 2014;1338(1):94–114.
Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of neurology. 2005;58(4):594–604.
Newman MP, Blum S, Wong RCW, Scott JG, Prain K, Wilson RJ, et al. Autoimmune encephalitis. Internal Medicine Journal. 2016;46(2):148–57.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. The Lancet Neurology. 2008;7(12):1091–8.
Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain : a journal of neurology. 2010;133(6):1655–67.
Johnson N, Henry C, Fessler AJ, Dalmau J. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology. 2010;75(16):1480–2.
Titulaer MJ, Dalmau J. Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. Neurology. 2014;82(7):550–1.
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis, et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75:411–428.
Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094–100.
ee R, Buckley C, Irani SR, Vincent A. Autoantibody testing in encephalopathies. Practical Neurology. 2012;12(1):4–13.
Gabilondo I, Saiz A, Galan L, Gonzalez V, Jadraque R, Sabater L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996–9.
Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al. Anti-NMDA receptor encephalitis in Japan: Long-term outcome without tumor removal. Neurology. 2007;70(7):504–11.
Sköldenberg B, Aurelius E, Hjalmarsson A, Sabri F, Forsgren M, Andersson B, et al. Incidence and pathogenesis of clinical relapse afer herpes simplex encephalitis in adults. Journal of neurology. 2005;253(2):163–70.
De Tiege X, Rozenberg F, Des Portes V, Lobut JB, Lebon P, Ponsot G, et al. Herpes simplex encephalitis relapses in children: Differentiation of two neurologic entities. Neurology. 2003;61(2):241–3.
Hargrave DR, Webb DW. Movement disorders in association with herpes simplex virus encephalitis in children: a review. Developmental Medicine & Child Neurology. 2008;40(9):640–2.
Titulaer MJ, Leypoldt F, Dalmau J. Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. Movement Disorders. 2013;29(1):3–6.
Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Annals of neurology. 2014;75(2):317–23.
Kleopa KA. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain : a journal of neurology. 2006;129(6):1570–84.
Newsom-Davis J. Autoimmune Neuromyotonia (Isaacs’ Syndrome): An Antibody-mediated Potassium Channelopathy. Annals of the New York Academy of Sciences. 1997;835(1 Frontiers of):111–9.
Barber PA, Anderson NE, Vincent A. Morvan’s syndrome associated with voltage-gated K channel antibodies. Neurology. 2000;54(3):771–2.
Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan’s fbrillary chorea: a paraneoplastic manifestation of thymoma. Journal of Neurology, Neurosurgery & Psychiatry. 1998;65(6):857–62.
Buckley C, Oger J, Clover L, Tüzün E, Carpenter K, Jackson M, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Annals of neurology. 2001;50(1):73–8.
Lai M, Huijbers MGM, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. The Lancet Neurology. 2010;9(8):776–85.
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contacting-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain : a journal of neurology. 2010;133(9):2734–48.
Lancaster E, Huijbers MGM, Bar V, Boronat A, Wong A, Martinez-Hernandez E, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Annals of neurology. 2011;69(2):303–11.
van Sonderen A, Schreurs MWJ, de Bruijn MAAM, Boukhrissi S, Nagtzaam MMP, Hulsenboom ESP, et al. Te relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology. 2016;86(18):1692–9.
Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of neurology. 2011;69(5):892–900.
Iranzo A, Graus F, Clover L, Morera J, Bruna J, Vilar C, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Annals of neurology. 2005;59(1):178–81.
McKeon A, Marnane M, O’Connell M, Stack JP, Kelly PJ, Lynch T. Potassium Channel Antibody–Associated Encephalopathy Presenting With a Frontotemporal Dementia–like Syndrome. Archives of Neurology. 2007;64(10):1528.
Geschwind MD, Tan KM, Lennon VA, Barajas RF Jr, Haman A, Klein CJ, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol. 2008;65(10):1341–1346.
Shin Y-W, Lee S-T, Shin J-W, Moon J, Lim J-A, Byun J-I, et al. VGKC-complex/LGI1-antibody encephalitis: Clinical manifestations and response to immunotherapy. Journal of Neuroimmunology. 2013;265(1–2):75–81.
van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger K-P, et al. The clinical spectrum of Caspr2 antibody–associated disease. Neurology. 2016;87(5):521–8.
Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Annals of neurology. 2009;65(4):424–34.
Hofberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology. 2015;84(24):2403–12.
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet Neurology. 2010;9(1):67–76.
Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology. 2013;81(10):882–7.
Hofberger R, Titulaer MJ, Sabater L, Dome B, Rozsas A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: Novel fndings in a new case series of 20 patients. Neurology. 2013;81(17):1500–6.
Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R,et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276–286.
Boronat A, Gelfand JM, Gresa-Arribas N, Jeong H-Y, Walsh M, Roberts K, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Annals of neurology. 2012;73(1):120–8.
Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83(20):1797–803.
Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S, Connolly S, et al. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology. 2008;71(16):1291–2.
Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blocker IM, et al. Progressive encephalomyelitis with rigidity and myoclonus: A new variant with DPPX antibodies. Neurology. 2014;82(17):1521–8.
Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain : a journal of neurology. 2014;137(8):2178–92.
Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–89.
Mat A, Adler H, Merwick A, Chadwick G, Gullo G, Dalmau JO, et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology. 2013;80(14):1349–50.
Marignier R, Chenevier F, Rogemond V, Sillevis Smitt P, Renoux C, Cavillon G, et al. Metabotropic Glutamate Receptor Type 1 Autoantibody–Associated Cerebellitis. Archives of Neurology. 2010;67(5).
Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain : a journal of neurology. 2012;135(11):3453–68.
Gresa-Arribas N, Planagumà J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, et al. Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86(24):2235–42.
Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. The Lancet Neurology. 2014;13(6):575–86.
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016;15(4):391–404.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
